Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: J Hepatol. 2021 Jan 13;74(6):1398–1406. doi: 10.1016/j.jhep.2020.12.021

Figure 3 (four panels): Observed survival times within quartiles of Metroticket and HALT-HCC scores relative to LiTES-HCC score categories.

Figure 3 (four panels):

Figure 3 (four panels):

Figure 3 (four panels):

Figure 3 (four panels):

a. Figure 3a: Observed mean survival time and 95% CI over 5-year time horizon for continuous Metroticket

b. Figure 3b: Observed mean survival time and 95% CI over 10-year time horizon for continuous Metroticket

c. Figure 3c: Observed mean survival time and 95% CI over 5-year time horizon for continuous HALT-HCC

d. Figure 3d: Observed mean survival time and 95% CI over 10-year time horizon for continuous HALT-HCC